3 Healthcare Mutual Funds To Grab As the Sector Continues to Rebound
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2024
0mins
Source: Benzinga
Healthcare Sector Performance in 2023:
- Healthcare sector lagged in 2023 compared to tech and growth stocks, rising only 0.3%.
- Despite being one of the worst-performing sectors, it ended the year with a late rally.
Growth and Outlook for Healthcare Sector:
- Health spending in the U.S. is projected to reach $6.2 trillion by 2028.
- Globally, around $8.3 trillion is spent on healthcare, with the U.S. contributing $3.8 trillion.
- Demographic changes like an aging population and health epidemics are driving sector growth.
Investment Opportunities in Healthcare:
- Healthcare stocks are considered defensive and offer stability in varying market conditions.
- Integration of AI in medical research and steady cash flow from pharmaceutical companies make the sector attractive for investors.
Healthcare Mutual Funds:
- Healthcare mutual funds like Janus Henderson Global Life Sciences, Vanguard Health Care, and Fidelity Select Pharmaceuticals are recommended.
- These funds have positive returns, low expense ratios, and minimum initial investments within $5000.
Specific Healthcare Mutual Funds:
- Janus Henderson Global Life Sciences (JNGLX), Vanguard Health Care (VGHCX), and Fidelity Select Pharmaceuticals Portfolio (FPHAX) are highlighted.
- Each fund has specific investment strategies, lead managers, top holdings, annualized returns, and Zacks Mutual Fund Rank.
Analyst Views on XLV
Wall Street analysts forecast XLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XLV is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 158.290
Low
Averages
High
Current: 158.290
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
